All regulatory updates
148 results found
AICIS varies AIIC listings after evaluation for multiple textile dye/printing ink chemicals, adding/amending SIRs with 20-working-day notification triggers
AICIS issued an inventory notice varying AIIC listing terms after evaluation for CAS 70693-64-0, 12222-80-9, 15141-18-1, 68516-81-4, 69766-79-6, and 72987-42-9. The variations include new SIRs and an amended SIR requiring introducers to notify AICIS of volume introduced and end use within 20 working days when specified conditions occur (e.g., end use changes beyond textile dyes/printing inks, use by non-professional workers, start of manufacturing, volume-related conditions, or new adverse environmental effects information—conditions vary by CAS). Compliance teams should map each CAS to its listing conditions and implement processes to detect trigger events and meet the 20-working-day notification timeframe.
AICIS varies AIIC listing after evaluation for CAS 3253-39-2, adding a Specific Information Requirement (SIR) with 20-working-day notification triggers
AICIS issued an inventory notice varying the Australian Inventory of Industrial Chemicals (AIIC) listing terms for CAS 3253-39-2 to add a Specific Information Requirement (SIR). The SIR requires introducers to notify the Executive Director about volume introduced and end use within 20 working days if the chemical is introduced for consumer end use (except articles). Compliance teams should review product end-use classifications and ensure internal triggers and recordkeeping support the 20-working-day reporting timeline when consumer end use occurs or changes.
EPA extends postponement of effectiveness for certain TSCA risk management provisions for trichloroethylene (TCE) until May 18, 2026
EPA published a final action extending the postponement of effectiveness for certain provisions of the TSCA risk management rule for trichloroethylene (TCE), specifically affecting conditions tied to TSCA section 6(g) exemptions, until May 18, 2026. This changes the timeline for when affected requirements become effective for entities relying on (or managing) exempted uses under the TCE rule. Compliance teams should reassess implementation schedules, contractual obligations, and operational controls tied to the postponed provisions.
Illinois SB1773 advances in House: placed on Calendar 2nd Reading (Short Debate)
Illinois SB1773 (104th General Assembly), which would amend the Illinois Controlled Substances Act to classify xylazine as a Class/Schedule III controlled substance and include specific statutory exemptions for certain veterinary/animal-drug and professional uses, advanced procedurally in the Illinois House. The ILGA bill status record shows the bill was placed on the House Calendar for 2nd Reading (Short Debate) on 2026-02-13. This is legislative progress and not enactment; compliance teams should treat the requirements as pending and monitor for passage, signature, and any finalized effective/implementation dates.
AICIS adds CAS 3113590-25-0 to the Australian Inventory of Industrial Chemicals (AIIC) 5 years after assessment certificate (s 82)
AICIS published an Inventory notice that an industrial chemical (CAS 3113590-25-0; 1-Pyrrolidinepropanaminium, N,N,N-trimethyl-2,5-dioxo-, 3-polyisobutenyl derivs., Me sulfates) was added to the Australian Inventory of Industrial Chemicals under section 82 of the Industrial Chemicals Act 2019 (addition 5 years after issue of an assessment certificate). The notice also reiterates that specific information requirement (SIR) obligations apply and introducers must notify AICIS within 28 days if their introduction circumstances differ from those described in AICIS’s assessment—relevant for ongoing compliance, record-keeping, and change management for import/manufacture conditions.
Illinois HB5046 introduced to amend 720 ILCS 570/311.6 on e-prescribing exceptions and pharmacy transfer/notification when initial e-prescription cannot be filled
Illinois HB5046 (104th General Assembly) was introduced on 2026-02-10 and proposes amendments impacting 720 ILCS 570/311.6 (electronic prescribing for Schedule II–V controlled substances). As described in the bill text, it would (1) require a dispenser/pharmacy that cannot fill an initial electronically received prescription due to out-of-stock conditions to immediately contact the patient and ask whether the prescription should be electronically transferred to a pharmacy of the patient’s choosing (consistent with 21 CFR 1306), and (2) expand/clarify exceptions to mandatory electronic prescribing where drugs may need to be filled outside typical retail hours or are difficult to obtain due to drug shortages/inventory limitations. The bill also contains conforming changes to the Pharmacy Practice Act (225 ILCS 85/19). Compliance teams at pharmacies, health systems, and prescriber organizations should monitor this bill because it would change operational workflows for patient communication and prescription transfer, and would adjust when non-electronic prescribing is permitted for controlled substances.
AICIS varies an AIIC listing following revocation of confidential business information (CBI) approval for CAS 403656-24-6
AICIS published an Inventory notice indicating a variation to an Australian Inventory of Industrial Chemicals (AIIC) listing due to revocation of a confidential business information (CBI) approval, identifying the affected substance by CAS 403656-24-6. For compliance teams, this signals that public inventory record content/identifiers associated with the listing may have changed following the CBI decision, which can affect substance identification, documentation, and downstream compliance communications. (Detailed notice text could not be extracted in the research run, but the official hub and notice URL corroborate the event and CAS number.)
AICIS publishes enforceable undertaking with MCo Beauty Pty Ltd (commenced 9 February 2026) regarding unauthorised industrial chemical introductions
AICIS published an enforceable undertaking with MCo Beauty Pty Ltd, commencing 9 February 2026. The undertaking relates to alleged unauthorised introductions of products containing industrial chemicals under the Industrial Chemicals Act 2019 framework. Commitments include quarantining relevant products (including where import volumes exceeded 100 kg in a registration year) pending destruction or re-export with evidence to AICIS within specified timeframes, and implementing documented compliance systems to prevent recurrence and ensure compliance with authorised introduction categories and related obligations. This signals AICIS enforcement expectations around introduction authorisation and internal compliance controls.
EPA proposes updates to TSCA Title VI formaldehyde emission standards for composite wood products (new QC test method and updated incorporated standards)
EPA issued a proposed rule to amend the Formaldehyde Emission Standards for Composite Wood Products regulations under TSCA Title VI by adding a new quality control test method (ISO 12460-2:2024(en) small-scale chamber method) and making technical updates to incorporated voluntary consensus standards. Compliance teams in the composite wood products supply chain should review the proposed updates to referenced standards/test methods and submit comments within the stated comment period once published in the Federal Register.
EPA proposes updates to incorporated voluntary consensus standards for TSCA Title VI formaldehyde emissions standards (incl. adding ISO 12460-2:2024 QC test method)
EPA issued a proposed rule to update the incorporation by reference (IBR) of multiple voluntary consensus standards in 40 CFR Part 770 (TSCA Title VI—Formaldehyde Emission Standards for Composite Wood Products). EPA also proposes adding ISO 12460-2:2024(en) as an additional small-scale quality control chamber test method and making related conforming updates (e.g., scope/definitions). Compliance teams in composite wood products and downstream supply chains should review whether current QA/QC testing methods and referenced standards would need updating if the rule is finalized, and should consider submitting comments to the docket by the stated deadline (March 13, 2026).
EPA publishes “year one” roundup of PFAS actions highlighting ongoing regulatory and enforcement initiatives
EPA issued a news release summarizing major PFAS actions taken during the first year of the administration, signaling continued cross-program PFAS priorities (e.g., regulatory actions, implementation efforts, and enforcement posture). While not itself a binding legal change, this roundup can influence compliance planning by indicating areas of anticipated scrutiny and policy direction.
EPA publishes ‘year one’ roundup of PFAS actions highlighting ongoing regulatory and enforcement initiatives
EPA issued a public roundup summarizing major PFAS actions taken during the first year of the current administration, including coordination and continued emphasis on regulatory and enforcement activities addressing PFAS risks. While the release is programmatic rather than a discrete rule text amendment, it can inform compliance teams about EPA priorities, active PFAS initiatives, and likely areas of near-term regulatory attention.
EPA final rule adds sodium perfluorohexanesulfonate (PFHxS‑Na) to TRI as a PFAS chemical of special concern (100 lb threshold); reporting starts 2026 with first reports due July 1, 2027
US EPA finalized a TRI rule adding sodium perfluorohexanesulfonate (PFHxS‑Na) to the Toxics Release Inventory as a PFAS chemical of special concern. Facilities subject to TRI must begin tracking releases and other reportable waste management quantities for PFHxS‑Na for the reporting period beginning January 1, 2026. The first Form R submissions covering PFHxS‑Na will be due July 1, 2027. The rule applies a 100 lb reporting threshold as a chemical of special concern, increasing compliance and data management obligations for TRI reporters handling PFHxS‑Na.
Illinois SB3521 introduced to amend 720 ILCS 570/318 regarding PMP data exchange definitions and automatic inquiry-system account creation tied to controlled substance licensure
SB3521 (104th General Assembly) was introduced on 2026-02-05 and proposes amendments to 720 ILCS 570/318 (Confidentiality of information) relating to the prescriber and dispenser inquiry system (PMP). The proposal would clarify that a “one-to-one secure link” includes communications exchange platforms aligned with widely adopted standards (including PMIX) to facilitate secure (including cross-state) PMP data transfer. The introduced text also includes provisions to automatically create a log-in to the inquiry system when a prescriber/dispenser obtains or renews a controlled substance license, and to require IDFPR to provide the PMP with electronic access to license information to facilitate profile creation. If enacted, it would affect prescriber/dispenser PMP access workflows, identity provisioning, and technical interoperability planning for organizations operating in Illinois.
U.S. Department of State release on 2026 Critical Minerals Ministerial references NOFO for a Rare Earth Elements Demonstration Facility
The U.S. Department of State published a release on the 2026 Critical Minerals Ministerial that references U.S. funding initiatives tied to critical minerals, including a Notice of Funding Opportunity (NOFO) to establish a Rare Earth Elements (REE) Demonstration Facility (referenced as dated Dec. 1, 2025 within the release). While programmatic rather than a binding regulation, it can affect compliance-relevant expectations for project eligibility, supply-chain due diligence, and procurement requirements for organizations seeking to participate in U.S.-supported REE initiatives.
ECHA refreshes the Registry of SVHC intentions until outcome (last updated 4 Feb 2026)
ECHA’s Registry of SVHC intentions until outcome shows an update (last updated 4 February 2026), reflecting the current status of SVHC identification intentions (e.g., intentions marked withdrawn or progressed). This is SVHC-relevant operational guidance for compliance and regulatory intelligence teams because it provides an official forward-looking view of substances that may be proposed for SVHC identification, supporting proactive supply-chain risk screening and substance substitution planning.
ECHA adds n-hexane and bisphenol AF (and its salts) to the REACH SVHC Candidate List (total 253 entries)
On 4 February 2026, ECHA updated the REACH Candidate List of Substances of Very High Concern (SVHCs) by adding two new entries: (1) n-hexane (EC 203-777-6; CAS 110-54-3), identified under REACH Article 57(f) (human health) due to specific target organ toxicity after repeated exposure; and (2) 4,4′-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and its salts (group entry including bisphenol AF and salts), identified under REACH Article 57(c) (toxic for reproduction). The Candidate List total increased to 253 entries. Compliance teams should assess impacts on downstream REACH SVHC obligations triggered by Candidate List inclusion, including Article 33 communication obligations for SVHCs in articles above 0.1% w/w, Article 7(2) notification duties for SVHCs in articles (within six months of inclusion date as described by ECHA), and ensuring SDS are updated when supplying the substances as such or in mixtures. The official Candidate List table serves as the authoritative record of inclusion and entry details.
ECHA updates Registry of SVHC intentions until outcome (last updated 4 Feb 2026)
ECHA refreshed the ‘Registry of SVHC intentions until outcome’ (page shows “Last updated 04 February 2026”), reflecting the current status of SVHC identification intentions and outcomes (e.g., entries marked as withdrawn/identified). While not a Candidate List inclusion itself, this update is directly relevant to REACH SVHC monitoring because it signals changes in the SVHC identification pipeline that compliance teams track for upcoming Candidate List proposals and consultations.
Illinois SB3221 proposed to schedule xylazine as a Class III controlled substance with exemptions; stated effective date Jan 1, 2027 (bill text)
SB3221 (104th General Assembly) proposes adding xylazine as a Class III (Schedule III) controlled substance under the Illinois Controlled Substances Act while providing that xylazine is not considered a controlled substance in specified circumstances (exemptions for certain legitimate uses). The bill PDF text indicates an effective date of 2027-01-01. Organizations that handle xylazine (including veterinary and related regulated activities) should monitor because scheduling would impose controlled-substance controls unless an exemption applies.
NIOSH opens Federal Register Request for Information (RFI) on firefighter safety portfolio; comments due April 3, 2026
CDC/NIOSH published a Federal Register Request for Information (RFI) seeking stakeholder input to help refine priorities for the NIOSH Center for Firefighter Safety, Health, and Well-Being research and service portfolio. The notice states it does not propose new regulations, requirements, or policies, but it is an official docketed action that can influence NIOSH priority-setting and downstream guidance, research, and program emphasis relevant to firefighter occupational safety and health. Compliance teams and affected stakeholders (fire departments, unions, PPE/respirator stakeholders, researchers) may wish to submit comments by the stated deadline and monitor follow-on outputs.